Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 327

1.

Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): an overview of Presentation and Pathogenesis and Guidelines for Pathological Diagnosis and Management.

Jones JL, Hanby AM, Wells C, Calaminici M, Johnson L, Turton P, Deb R, Provenzano E, Shaaban A, Ellis I, Pinder S; National Co-ordinating Committee of Breast Pathology.

Histopathology. 2019 Jun 5. doi: 10.1111/his.13932. [Epub ahead of print]

PMID:
31166611
2.

The SMALL Trial: A Big Change for Small Breast Cancers.

Morgan J, Potter S, Sharma N, McIntosh SA; SMALL Trial Management Group, Coles CE, Dodwell D, Elder K, Gaunt C, Lyburn ID, McIntosh SA, Morgan J, Paramasivan S, Pinder S, Pirrie S, Potter S, Rea D, Roberts T, Sharma N, Stobart H, Taylor-Phillips S, Wallis M, Wilcox M.

Clin Oncol (R Coll Radiol). 2019 May 31. pii: S0936-6555(19)30200-6. doi: 10.1016/j.clon.2019.05.008. [Epub ahead of print] No abstract available.

PMID:
31160130
3.

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.

Petridis C, Arora I, Shah V, Megalios A, Moss C, Mera A, Clifford A, Gillett C, Pinder SE, Tomlinson I, Roylance R, Simpson MA, Sawyer EJ.

Breast Cancer Res. 2019 May 6;21(1):58. doi: 10.1186/s13058-019-1143-y.

4.

No evidence that portion size influences food consumption in male Sprague Dawley rats.

Naneix F, Pinder SC, Summers MY, Rouleau RM, Robinson E, Myers KP, McCutcheon JE.

Physiol Behav. 2019 Jul 1;206:225-231. doi: 10.1016/j.physbeh.2019.04.013. Epub 2019 Apr 18.

PMID:
31004618
5.

Repression of Transcription at DNA Breaks Requires Cohesin throughout Interphase and Prevents Genome Instability.

Meisenberg C, Pinder SI, Hopkins SR, Wooller SK, Benstead-Hume G, Pearl FMG, Jeggo PA, Downs JA.

Mol Cell. 2019 Jan 17;73(2):212-223.e7. doi: 10.1016/j.molcel.2018.11.001. Epub 2018 Dec 13.

6.

Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients.

Chatterjee G, Pai T, Hardiman T, Avery-Kiejda K, Scott RJ, Spencer J, Pinder SE, Grigoriadis A.

Breast Cancer Res. 2018 Nov 20;20(1):143. doi: 10.1186/s13058-018-1070-3. Review.

7.

A conceptual framework for training of trainers (ToT) interventions in global health.

Mormina M, Pinder S.

Global Health. 2018 Oct 22;14(1):100. doi: 10.1186/s12992-018-0420-3.

8.

Bilateral Inflammatory Pseudotumour of the Breast: A Case Report and Review of the Literature.

Dani M, Pinder S, Fentiman I.

Eur J Breast Health. 2018 Oct 1;14(4):229-233. doi: 10.5152/ejbh.2018.4150. eCollection 2018 Oct.

9.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby A, Thomas JSJ, Maxwell AJ, Wallis MG, Dodwell DJ; Sloane Project Steering Group (NHS Prospective Study of Screen-Detected Non-invasive Neoplasias).

Eur J Cancer. 2018 Sep;101:210-219. doi: 10.1016/j.ejca.2018.06.027. Epub 2018 Aug 6.

PMID:
30092498
10.

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall M, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder S, Nestle FO, Gillett C, Spicer JF, Grigoriadis A, Tutt ANJ, Karagiannis SN.

Clin Cancer Res. 2018 Oct 15;24(20):5098-5111. doi: 10.1158/1078-0432.CCR-18-0652. Epub 2018 Aug 1.

11.

Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.

Dodson A, Parry S, Ibrahim M, Bartlett JM, Pinder S, Dowsett M, Miller K.

J Pathol Clin Res. 2018 Oct;4(4):262-273. doi: 10.1002/cjp2.112. Epub 2018 Sep 21.

12.

Effects of Ivabradine on Hemodynamic and Functional Parameters in Left Ventricular Systolic Dysfunction: a Systematic Review and Meta-analysis.

Patel PA, Ali N, Roy A, Pinder S, Cubbon RM, Kearney MT, Witte KK.

J Gen Intern Med. 2018 Sep;33(9):1561-1570. doi: 10.1007/s11606-018-4578-4. Epub 2018 Jul 18.

PMID:
30022413
13.

NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions).

Pinder SE, Shaaban A, Deb R, Desai A, Gandhi A, Lee AHS, Pain S, Wilkinson L, Sharma N.

Clin Radiol. 2018 Aug;73(8):682-692. doi: 10.1016/j.crad.2018.04.004.

PMID:
29773220
14.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

15.

Diagnostic concordance of reporting lymphovascular invasion in breast cancer.

Rakha EA, Abbas A, Pinto Ahumada P, ElSayed ME, Colman D, Pinder SE, Ellis IO.

J Clin Pathol. 2018 Sep;71(9):802-805. doi: 10.1136/jclinpath-2017-204981. Epub 2018 Mar 29.

PMID:
29599396
16.

The importance of histological assessment after neoadjuvant therapy and the need for standardisation.

Naidoo K, Pinder SE.

Clin Radiol. 2018 Aug;73(8):693-699. doi: 10.1016/j.crad.2018.01.005. Epub 2018 Feb 10. Review.

PMID:
29439778
17.

Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers.

Grigoriadis A, Gazinska P, Pai T, Irhsad S, Wu Y, Millis R, Naidoo K, Owen J, Gillett CE, Tutt A, Coolen AC, Pinder SE.

J Pathol Clin Res. 2018 Jan 8;4(1):39-54. doi: 10.1002/cjp2.87. eCollection 2018 Jan.

18.

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.

Maxwell AJ, Clements K, Hilton B, Dodwell DJ, Evans A, Kearins O, Pinder SE, Thomas J, Wallis MG, Thompson AM; Sloane Project Steering Group.

Eur J Surg Oncol. 2018 Apr;44(4):429-435. doi: 10.1016/j.ejso.2017.12.007. Epub 2018 Jan 11.

PMID:
29398324
19.

Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ.

Masannat YA, Husain E, Roylance R, Heys SD, Carder PJ, Ali H, Maurice Y, Pinder SE, Sawyer E, Shaaban AM.

Breast. 2018 Apr;38:120-124. doi: 10.1016/j.breast.2017.12.011. Epub 2018 Jan 5.

PMID:
29310036
20.

Invasion in breast lesions: the role of the epithelial-stroma barrier.

Rakha EA, Miligy IM, Gorringe KL, Toss MS, Green AR, Fox SB, Schmitt FC, Tan PH, Tse GM, Badve S, Decker T, Vincent-Salomon A, Dabbs DJ, Foschini MP, Moreno F, Wentao Y, Geyer FC, Reis-Filho JS, Pinder SE, Lakhani SR, Ellis IO.

Histopathology. 2018 Jun;72(7):1075-1083. doi: 10.1111/his.13446. Epub 2018 Feb 13. Review.

PMID:
29197112
21.

Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial.

Rea D, Francis A, Wallis M, Thomas J, Bartlett J, Bowden S, Dodwell D, Fallowfield L, Gaunt C, Hanby A, Jenkins V, Matthews L, Pinder S, Pirrie S, Reed M, Wilcox M, Roberts T, Kirwan C, Brookes C, Fairbrother P, Billingham L, Evans A, Young J.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):566-567. doi: 10.1245/s10434-017-6174-y. Epub 2017 Nov 28. No abstract available.

PMID:
29185098
22.

Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.

Lawler K, Papouli E, Naceur-Lombardelli C, Mera A, Ougham K, Tutt A, Kimbung S, Hedenfalk I, Zhan J, Zhang H, Buus R, Dowsett M, Ng T, Pinder SE, Parker P, Holmberg L, Gillett CE, Grigoriadis A, Purushotham A.

Breast Cancer Res. 2017 Oct 13;19(1):113. doi: 10.1186/s13058-017-0881-y.

23.

Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?

Van Bockstal M, Libbrecht L, Floris G, Lambein K, Pinder S.

Ann Oncol. 2017 Sep 1;28(9):2317. doi: 10.1093/annonc/mdx253. No abstract available.

PMID:
28911076
24.

High-intensity focused ultrasound in the treatment of breast fibroadenomata (HIFU-F trial).

Peek MCL, Ahmed M, Scudder J, Baker R, Charalampoudis P, Pinder SE, Douek M; HIFU-F Collaborators.

Int J Hyperthermia. 2018 Nov;34(7):1002-1009. doi: 10.1080/02656736.2017.1373865. Epub 2017 Oct 2.

PMID:
28854826
25.

Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice.

Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM.

Clin Oncol (R Coll Radiol). 2017 Oct;29(10):642-652. doi: 10.1016/j.clon.2017.06.003. Epub 2017 Jun 29. Review.

26.

Use of a handheld terahertz pulsed imaging device to differentiate benign and malignant breast tissue.

Grootendorst MR, Fitzgerald AJ, Brouwer de Koning SG, Santaolalla A, Portieri A, Van Hemelrijck M, Young MR, Owen J, Cariati M, Pepper M, Wallace VP, Pinder SE, Purushotham A.

Biomed Opt Express. 2017 May 9;8(6):2932-2945. doi: 10.1364/BOE.8.002932. eCollection 2017 Jun 1.

27.

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O'Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van 't Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR.

Nature. 2017 Mar 30;543(7647):714-718. doi: 10.1038/nature21703. Epub 2017 Mar 22.

28.

Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.

Pinder SE, Campbell AF, Bartlett JM, Marshall A, Allen D, Falzon M, Dunn JA, Makris A, Hughes-Davies L, Stein RC.

Br J Cancer. 2017 Mar 28;116(7):859-863. doi: 10.1038/bjc.2017.28. Epub 2017 Feb 21.

29.

Automated Classification of Breast Cancer Stroma Maturity From Histological Images.

Reis S, Gazinska P, Hipwell JH, Mertzanidou T, Naidoo K, Williams N, Pinder S, Hawkes DJ.

IEEE Trans Biomed Eng. 2017 Oct;64(10):2344-2352. doi: 10.1109/TBME.2017.2665602. Epub 2017 Feb 7.

PMID:
28186876
30.

PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.

Shah V, Nowinski S, Levi D, Shinomiya I, Kebaier Ep Chaabouni N, Gillett C, Grigoriadis A, Graham TA, Roylance R, Simpson MA, Pinder SE, Sawyer EJ.

Breast Cancer Res. 2017 Jan 17;19(1):7. doi: 10.1186/s13058-016-0789-y.

31.

RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers.

Irshad S, Flores-Borja F, Lawler K, Monypenny J, Evans R, Male V, Gordon P, Cheung A, Gazinska P, Noor F, Wong F, Grigoriadis A, Fruhwirth GO, Barber PR, Woodman N, Patel D, Rodriguez-Justo M, Owen J, Martin SG, Pinder SE, Gillett CE, Poland SP, Ameer-Beg S, McCaughan F, Carlin LM, Hasan U, Withers DR, Lane P, Vojnovic B, Quezada SA, Ellis P, Tutt AN, Ng T.

Cancer Res. 2017 Mar 1;77(5):1083-1096. doi: 10.1158/0008-5472.CAN-16-0598. Epub 2017 Jan 12.

32.

Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival.

Gracio F, Burford B, Gazinska P, Mera A, Mohd Noor A, Marra P, Gillett C, Grigoriadis A, Pinder S, Tutt A, de Rinaldis E.

Sci Rep. 2017 Jan 6;7:40177. doi: 10.1038/srep40177.

33.

Reply to R.F. Sweis et al.

Schmid P, Pinder SE, Purushotham A, Thompson AM.

J Clin Oncol. 2017 Jan 10;35(2):261-262. Epub 2016 Oct 31. No abstract available.

PMID:
28056198
34.

Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme.

Rakha EA, Ahmed MA, Aleskandarany MA, Hodi Z, Lee AH, Pinder SE, Ellis IO.

Histopathology. 2017 Mar;70(4):632-642. doi: 10.1111/his.13117. Epub 2016 Dec 28.

PMID:
28028831
35.

Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?

Toss MS, Pinder SE, Green AR, Thomas J, Morgan DA, Robertson JF, Ellis IO, Rakha EA.

Histopathology. 2017 Apr;70(5):681-692. doi: 10.1111/his.13116. Epub 2016 Dec 20. Review.

PMID:
28000325
36.

Microstructural models for diffusion MRI in breast cancer and surrounding stroma: an ex vivo study.

Bailey C, Siow B, Panagiotaki E, Hipwell JH, Mertzanidou T, Owen J, Gazinska P, Pinder SE, Alexander DC, Hawkes DJ.

NMR Biomed. 2017 Feb;30(2). doi: 10.1002/nbm.3679. Epub 2016 Dec 21.

37.

Modern therapies and iatrogenic changes in breast pathology.

Provenzano E, Pinder SE.

Histopathology. 2017 Jan;70(1):40-55. doi: 10.1111/his.13098. Review.

PMID:
27960235
38.

The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.

Parham DM, Pinder SE.

Histopathology. 2017 May;70(6):1009-1011. doi: 10.1111/his.13145. Epub 2017 Feb 7. No abstract available.

PMID:
27943389
39.

The B3 conundrum-the radiologists' perspective.

Sharma N, Wilkinson LS, Pinder SE.

Br J Radiol. 2017 Mar;90(1071):20160595. doi: 10.1259/bjr.20160595. Epub 2016 Dec 12. Review.

40.

Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using 18F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study.

Grootendorst MR, Cariati M, Pinder SE, Kothari A, Douek M, Kovacs T, Hamed H, Pawa A, Nimmo F, Owen J, Ramalingam V, Sethi S, Mistry S, Vyas K, Tuch DS, Britten A, Van Hemelrijck M, Cook GJ, Sibley-Allen C, Allen S, Purushotham A.

J Nucl Med. 2017 Jun;58(6):891-898. doi: 10.2967/jnumed.116.181032. Epub 2016 Dec 8.

41.

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.

Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T.

Oncotarget. 2016 Aug 9;7(32):51012-51026. doi: 10.18632/oncotarget.9963.

42.

Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast.

Naidoo K, Beardsley B, Carder PJ, Deb R, Fish D, Girling A, Hales S, Howe M, Wastall LM, Lane S, Lee AH, Philippidou M, Quinn C, Stephenson T, Pinder SE.

J Clin Pathol. 2016 Dec;69(12):1122-1123. doi: 10.1136/jclinpath-2016-203886. Epub 2016 Aug 10.

PMID:
27510520
43.

Micro- and macro-metastasis in the axillary lymph node: A review.

Naidoo K, Pinder SE.

Surgeon. 2017 Apr;15(2):76-82. doi: 10.1016/j.surge.2016.07.002. Epub 2016 Aug 3. Review.

PMID:
27498412
44.

An audit of residual cancer burden reproducibility in a UK context.

Naidoo K, Parham DM, Pinder SE.

Histopathology. 2017 Jan;70(2):217-222. doi: 10.1111/his.13054. Epub 2016 Sep 27.

PMID:
27496095
45.

High intensity focused ultrasound in the treatment of breast fibroadenomata: results of the HIFU-F trial.

Peek MC, Ahmed M, Scudder J, Baker R, Pinder SE, Douek M; HIFU-F Trialists’ Group.

Int J Hyperthermia. 2016 Dec;32(8):881-888. Epub 2016 Sep 7.

PMID:
27484113
46.

Review of the national external quality assessment (EQA) scheme for breast pathology in the UK.

Rakha EA, Bennett RL, Coleman D, Pinder SE, Ellis IO; UK National Coordinating Committee for Breast Pathology (EQA Scheme Steering Committee).

J Clin Pathol. 2017 Jan;70(1):51-57. doi: 10.1136/jclinpath-2016-203800. Epub 2016 Jul 12.

PMID:
27406051
47.

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C.

Nat Commun. 2016 Jun 6;7:11908. doi: 10.1038/ncomms11908. No abstract available.

48.

Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.

Melvin JC, Purushotham AD, Garmo H, Pinder SE, Fentiman IS, Gillett C, Mera A, Lüchtenborg M, Holmberg L, Van Hemelrijck M.

Br J Cancer. 2016 Jun 14;114(12):e23. doi: 10.1038/bjc.2016.135. Epub 2016 May 26. No abstract available.

49.

Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer.

Woodman N, Pinder SE, Tajadura V, Le Bourhis X, Gillett C, Delannoy P, Burchell JM, Julien S.

Int J Oncol. 2016 Jul;49(1):265-75. doi: 10.3892/ijo.2016.3521. Epub 2016 May 13.

PMID:
27176937
50.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C.

Nat Commun. 2016 May 10;7:11479. doi: 10.1038/ncomms11479.

Supplemental Content

Loading ...
Support Center